Validation of the prognostic value of lymph node ratio in patients with cutaneous melanoma: A population-based study of 8,177 cases

Surgery

Volumn 150, Issue 1, 2011, Pages 83-90

  Mocellin, Simone ^a   Pasquali, Sandro ^a   Riccardo Rossi, Carlo ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SKIN CANCER; VALIDATION STUDY;

ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SKIN NEOPLASMS;

EID: 79959361231     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2011.02.021     Document Type: Article

References (35)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701. (Pubitemid 40260892)
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
3. Doben AR, MacGillivray DC. Current concepts in cutaneous melanoma: malignant melanoma. Surg Clin North Am 2009;89:713-25.
4. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:587-95.
5. Haass NK, Smalley KS. Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther 2009;13:283-96.
6. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101:452-74.
7. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-49. (Pubitemid 38812179)
8. NCCN. Melanoma. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Available: www.nccn.org; 2009.
9. Rossi CR, Mocellin S, Pasquali S, Pilati P, Nitti D. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol 2008;15:310-5.
10. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, et al. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 2009;115:2505-13.
11. Surveillance Epidemiology and End Results. Bethesda: National Cancer Institute; 2009.
12. SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973-2006 varying). Bethesda: National Cancer Institute; 2009.
13. Surveillance Research Program, SEER*Stat software. Bethesda: National Cancer Institute; 2009.
14. Spillane AJ, Cheung BL, Stretch JR, Scolyer RA, Shannon KF, Quinn MJ, et al. Proposed quality standards for regional lymph node dissections in patients with melanoma. Ann Surg 2009;249:473-80.
15. Klein J, Moeschberger M. Survival analysis: techniques for censored and truncated data. New York: Springer; 2003.
16. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis Part III: multivariate data analysis - choosing a model and assessing its adequacy and fit. Br J Cancer 2003;89:605-11. (Pubitemid 37076159)
17. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109-20. (Pubitemid 128480552)
18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233)
19. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-23. (Pubitemid 38968032)
20. Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 2000;56:249-55. (Pubitemid 30165116)
21. Marchet A, Mocellin S, Ambrosi A, Morgagni P, Garcea D, Marrelli D, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 2007;245:543-52.
22. Inoue K, Nakane Y, Iiyama H, Sato M, Kanbara T, Nakai K, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002;9:27-34. (Pubitemid 34262894)
23. Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002;9:775-84.
24. Xu DZ, Geng QR, Long ZJ, Zhan YQ, Li W, Zhou ZW, et al. Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol 2009;16:319-26.
25. Deng J, Liang H, Sun D, Pan Y. The prognostic analysis of lymph node-positive gastric cancer patients following curative resection. J Surg Res 2010;164:47-53.
26. Fukuda N, Sugiyama Y, Midorikawa A, Mushiake H. Prognostic Significance of the Metastatic Lymph Node Ratio in Gastric Cancer Patients. World J Surg 2009;33:2378-82.
27. Hatoum HA, Jamali FR, El-Saghir NS, Musallam KM, Seoud M, Dimassi H, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol 2009;16:3388-95.
28. Truong PT, Vinh-Hung V, Cserni G, Woodward WA, Tai P, Vlastos G. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008;44:1670-7.
29. Yildirim E, Berberoglu U. Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg 2007;31:276-89. (Pubitemid 46183511)
30. Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, et al. Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon Rectum 2009;52:1244-50.
31. Moug SJ, Saldanha JD, McGregor JR, Balsitis M, Diament RH. Positive lymph node retrieval ratio optimises patient staging in colorectal cancer. Br J Cancer 2009;100:1530-3.
32. Park IJ, Choi GS, Jun SH. Nodal stage of stage III colon cancer: the impact of metastatic lymph node ratio. J Surg Oncol 2009;100:240-3.
33. Lee HY, Choi HJ, Park KJ, Shin JS, Kwon HC, Roh MS, et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 2007;14:1712-7.
34. Dummer R, Hauschild A, Pentheroudakis G. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4):129-31.
35. Spillane AJ, Winstanley J, Thompson JF. Lymph node ratio in melanoma: a marker of variation in surgical quality? Cancer 2009;115:2384-7.